Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015; and clinical collaboration with Bristol Myers Squibb to evaluate ERAS-0015 in clinical study. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.…
Erasca (ERAS) Stock Fair Value Edges Higher After ERAS 0015 Analyst Optimism
Erasca (NASDAQ: ERAS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 103 employees.
The shares were at 13.61 USD on 20 November 2026, up 499.6% over 52 weeks. Its 52-week range is 2.210 USD to 24.28 USD: the price is 43.9% below the high and 515.8% above the low.
Its market capitalisation is 4.78B USD.
Erasca reports return on equity of -38.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 600.29M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 10 analysts cover the stock, with an average rating of Buy; their mean price target of 25.10 USD is 84.4% above the current price. The next earnings report is expected on 11 March 2027.